Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.
Short pieces of RNA, known as small interfering RNA (siRNA), have the potential to become a new class of anticancer drugs if researchers can solve the problem of how to deliver these fragile molecules to cancer cells.
A promising approach to gene therapy involves short DNA fragments (interfering RNA) that bind to specific genes and block their "translation" into the corresponding, disease-related protein.
Cancer researchers hold great hope that nucleic acid-based therapeutics, such as anticancer genes, antisense oligonucleotides, and small interfering RNA (siRNA) molecules, will prove to be powerful antitumor agents.
Researchers at Johns Hopkins have discovered that a tiny piece of genetic code apparently goes where no bit of it has gone before, and it gets there under its own internal code.
Efforts to treat cancer using genes and other oligonucleotides, such as short interfering RNA (siRNA), that turn off the biochemical processes that trigger malignancies have been hindered by difficulties in delivering nucleic acids to tumors.
A single gene plays a pivotal role launching two DNA damage detection and repair pathways in the human genome, suggesting that it functions as a previously unidentified tumor suppressor gene.
Sirna Therapeutics has announced that its objections to the Kreutzer-Limmer patent in Europe were accepted by the European Patent Office.
Using one of the newest and most powerful tools of biomedical science, University of Texas Medical Branch at Galveston (UTMB) researchers have scored a dramatic success in the battle against colorectal cancer.
A technical advance in laboratory techniques may provide biology researchers broader access to RNA interference, a process of blocking the activity of targeted genes. RNA interference has recently emerged as an important tool in studying how genes function in normal biological processes and in disease.
Various forms of human muscular dystrophy result from mutations in genes encoding proteins of the nuclear envelope. A new paper in the February 15th issue of G&D reveals how.
Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).
...according to research published today in Physical Review Letters, "Dynamics and Spatial Organization of Endosomes in Mammalian Cells."
In mice, that had been genetically engineered to develop Alzheimer's disease, scientists were able to reverse the rodents' memory loss by reducing the amount of an enzyme that is crucial for the development of Alzheimer's disease.
Intradigm Corporation announced today its collaboration with Chinese academic and biotech groups has achieved clear evidence of prophylactic and therapeutic effects of siRNA (small interfering RNA) agents in Rhesus monkey to treat SARS coronavirus (SCV) respiratory infection.
...has begun at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. Working within the MitoCheck consortium that includes 10 other institutes throughout Europe, the EMBL scientists will silence all human genes, one-by-one, to find those involved in cell division (mitosis) and to answer fundamental questions of how cell division is regulated.
Sirna Therapeutics has announced that the United Kingdom (UK) Patent Office has granted the Company two additional short interfering RNA (siRNA) target patents. The first patent covers any siRNA with one or more chemical modifications targeting Vascular Endothelial Growth Factor (VEGF).
For the first time, scientists have shown that humans use an immune defense process common in plants and invertebrates to battle a virus.
Researchers at the University of Dundee have identified a way of inactivating a naturally occurring human protein, a development which could offer new routes to developing cancer prevention treatments.
Sirna Therapeutics announced today that its collaborator at the University of Iowa, Dr. Beverly Davidson, published groundbreaking results for the potential treatment of Huntington's Disease (HD).
Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.